Reversal Agents
In adult patients (GCS ≥8) with spontaneous supratentorial intracerebral hemorrhage who were on antiplatelet therapy and presented within 6 hours, does platelet transfusion plus standard care, compared with standard care alone, reduce death or dependence at 3 months?
In adult patients with VKA-associated intracerebral hemorrhage (INR ≥2.0, symptoms <12h), does prothrombin complex concentrate (PCC) compared with fresh frozen plasma (FFP), both with vitamin K, lead to more rapid and effective INR normalization and affect hematoma expansion and clinical outcomes?
In adult patients with acute intracerebral hemorrhage treated within 4 hours of onset, does recombinant activated factor VII (rFVIIa) at doses of 20 μg/kg or 80 μg/kg, compared with placebo, reduce death or severe disability at 90 days?
More topics:
- Acute Blood Pressure Control
- Anti-fibrinolytic Therapy
- Anticoagulant Reversal
- Anticoagulation Reversal
- Antiplatelet Therapy Complications
- Craniotomy
- Deferoxamine
- External Ventricular Drain (EVD)
- Factor VIIa
- Fever Prevention
- Fresh Frozen Plasma (FFP)
- Glucose Control
- Hematoma Evacuation
- Hematoma Expansion
- Hemostasis
- Imaging Biomarkers
- Insulin Therapy
- Intraventricular Hemorrhage
- Iron Chelation
- Ischemic Stroke Management
- Minimally Invasive Surgery
- Neurocritical Care
- Neuroprotection
- Neurosurgical Intervention
- Prothrombin Complex Concentrate (PCC)
- Reversal Agents
- Secondary Brain Injury
- Supportive Care
- Temperature Management
- Thrombolysis (Alteplase)
- Tranexamic Acid
- Warfarin Reversal